-- Indicative Announcement on Changes in Equity Interests Reaching a Multiple of 5% by Shareholders and Directors Holding 5% or More of Shares and Their Persons Acting in Concert
Securities code: 688799 Securities abbreviation: Warner Pharmaceuticals Announcement number: 2025-074
Hunan Warner Pharmaceutical Co., Ltd.
Indicative announcement regarding changes in the equity interests of shareholders, directors and persons acting in concert holding more than 5% of the shares touching an integral multiple of 5%
Mr. Xu Yan and his person acting in concert, Mr. Xu Xiaoqiang, guarantee that the information provided to the company is true, accurate and complete, and contains no false records, misleading statements or major omissions.
The company's board of directors and all directors guarantee that the content of the announcement is consistent with the information provided by the information disclosure obligor.
Important content reminder:
Direction of equity change Proportion increase□ Proportion decreaseTotal proportion before equity change 15.57%
Total ratio after changes in equity 15.00%
Does this change violate the commitments, intentions, and plans made? Yes□ No
Whether the mandatory tender offer obligation is triggered? Yes□ No
1. Basic information of information disclosure obligors and persons acting in concert
- Identity Category
□Controlling shareholder/actual controller and persons acting in concert
Other major shareholders with more than 5% and their persons acting in concert
Investors and their consensus
□The largest shareholder and its persons acting in concert on the basis of merger (only applicable to persons without controlling shares)
East, actual controller)
□Other______________
- Information of information disclosure obligor
Information disclosure obligor
Investor identity Unified social credit code name
□ Controlling shareholder/actual controller
□ _____________Xu Xiaoqiang □ Person acting in concert with the controlling shareholder/actual controller
Not applicable
Other direct shareholders
- Information about persons acting in concert
Name of person acting in concert Investor identity Unified social credit code Controlling shareholder/actual controller
□ _____________Xu Yan □ Person acting in concert with the controlling shareholder/actual controller
Not applicable
Other direct shareholders
2. Basic situation where changes in equity touch an integral multiple of 5%
Hunan Warner Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") disclosed the "Announcement on the Plan to Reduce Shareholdings of Concert Acting Persons of Shareholders and Directors of Hunan Warner Pharmaceutical Co., Ltd. holding more than 5% of the shares" (Announcement Number: 2025-067) on the Shanghai Stock Exchange website (www.sse.com.cn) on July 28, 2025. Based on his own capital needs, Mr. Xu Xiaoqiang, a shareholder of the company, plans to reduce his holdings of the company's shares by no more than 1,300,000 shares within 3 months after 15 trading days from the date of the announcement of the shareholding reduction, through centralized bidding transactions or block transactions.
The company received a simplified equity change report issued by the information disclosure obligor on September 3, 2025. From September 1, 2025 to September 3, 2025, Mr. Xu Xiaoqiang reduced his holdings of the company's shares by a total of 757,120 shares through centralized bidding transactions, accounting for 0.58% of the company's total share capital. The total shareholding ratio of Mr. Xu Xiaoqiang and Mr. Xu Yan decreased from 15.57% to 15.00%, and the shareholding ratio touched an integer multiple of the 5% mark. The changes in equity this time are as follows:
Funds come from investors. Number of shares before change. Number of shares before change. Number of shares after change. After change. Source of change in equity (only
Equity change method
Name (10,000 shares) Proportion (%) (10,000 shares) Proportion (%) Time interval Holding increase fill
(write) Entities that directly change shareholdings:
Centralized bidding
2025/9/1-20 Xu Xiaoqiang 197.0920 1.50 121.3800 0.92 Block Transaction □ / 25/9/3
Others:____
Entities that have not directly changed their shareholdings:
Xu Yan 1,848.0000 14.07 1,848.0000 14.07 / / /Total 2,045.0920 15.57 1,969.3800 15.00 -- -- --Note: The data tail difference is due to rounding to two decimal places.
3. Other instructions
(1) This change in equity belongs to the reduction of shares held by shareholders and does not involve a tender offer.
(2) This change in equity is due to Xu Xiaoqiang, a shareholder and director acting in concert with Xu Yanzhi, who holds more than 5% of the company’s shares, fulfilling the previously disclosed share reduction plan. For details of the share reduction plan, please refer to the company’s announcement on July 28, 2025. The "Announcement on Plan to Reduce Shareholdings of Shareholders and Directors Acting in Concert of Hunan Warner Pharmaceutical Co., Ltd. Holding more than 5% of the shares" was disclosed on the Shanghai Stock Exchange (www.sse.com.cn) on the same day (Announcement Number: 2025-067).
(3) This change in equity is that Xu Xiaoqiang, a shareholder who holds more than 5% of the company's shares and director Xu Yan, who is acting in concert, has reduced his holdings of the company's shares. The above-mentioned shareholders are not the company's controlling shareholders, actual controllers and persons acting in concert. This change in equity will not lead to changes in the company's controlling shareholders and actual controllers, and will not have a significant impact on the company's governance structure and ongoing operations.
(4) According to relevant regulations such as the "Securities Law of the People's Republic of China", "Measures for the Administration of Acquisitions of Listed Companies" and "Guidelines No. 15 on the Content and Format of Information Disclosure by Companies Offering Securities to the Public - Equity Change Report", this change in equity involves the information disclosure obligor to disclose a simplified equity change report. For details, please refer to the "Hunan Warner Pharmaceutical Co., Ltd. Simplified Equity Change Report" disclosed by the company on the website of the Shanghai Stock Exchange (www.sse.com.cn) on the same day.
(5) After this equity change, the information disclosure obligor is still in the implementation period of its shareholding reduction plan. The company will continue to urge the information disclosure obligor to strictly implement the relevant regulations on shareholding reduction and disclose relevant information to investors in a timely manner. Investors are advised to pay attention to investment risks.
Announcement is hereby made.
Board of Directors of Hunan Warner Pharmaceutical Co., Ltd.
September 4, 2025